Urogenital Neoplasms  >>  oxaliplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

24 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT00004203: Oxaliplatin in Treating Patients With Metastatic Bladder Cancer

Completed
2
20
US, Canada
oxaliplatin
University of Chicago, National Cancer Institute (NCI)
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
02/02
04/05
NCT00782041: Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer

Terminated
2
11
RoW
Oxaliplatin, 5-FluoroUracil, Folinic acid
Sanofi
Uterine Neoplasms
08/03
 
NCT00005837: Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer

Completed
2
US, Canada
oxaliplatin
Gynecologic Oncology Group, National Cancer Institute (NCI)
Cervical Cancer
 
06/04
NCT00005836: Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Completed
2
US, Canada
oxaliplatin
Gynecologic Oncology Group, National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cavity Cancer
 
07/04
NCT00612495: Endometrial Cancer - LOHP Alone and With 5FU

Completed
2
31
Europe
oxaliplatin, 5 FU, Eloxatin, Fluorouracil
Sanofi
Endometrial Cancer
 
03/05
NCT00091182: Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

Completed
2
180
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP
National Cancer Institute (NCI)
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Recurrent Adrenocortical Carcinoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer
02/06
 
NCT00186277: Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

Completed
2
10
US
Oxaliplatin, Eloxatin, Taxotere, Docetaxel
Stanford University, Sanofi-Synthelabo
Bladder Cancer
12/06
12/06
NCT00260611: Study of Oxaliplatin and Taxotere in Prostate Cancer

Completed
2
34
US
Oxaliplatin, eloxatin, Taxotere, Docefrez, Docetaxel
University of Pittsburgh, Sanofi
Prostate Cancer
09/07
09/07
NCT00627432: Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Suspended
2
100
Europe
gemcitabine hydrochloride, oxaliplatin
Institut du Cancer de Montpellier - Val d'Aurelle
Bladder Cancer
03/09
 
NCT00057863: Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer

Completed
2
35
US
Paclitaxel, Anzatax, TAX, Oxaliplatin
National Cancer Institute (NCI)
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
12/09
03/10
NCT00418093: Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

Terminated
2
19
US
Gemcitabine, Oxaliplatin, Bevacizumab
Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, Eli Lilly and Company, Sanofi-Synthelabo, Genentech, Inc.
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
01/11
10/11
NCT00313612: Oxaliplatin and Topotecan in Advance Ovarian Cancer

Terminated
2
39
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, topotecan, hycamptamine, Hycamtin, SKF S-104864-A, TOPO
National Cancer Institute (NCI)
Recurrent Ovarian Epithelial Cancer
05/11
12/12
TEACO, NCT00296816: Taxotere, Eloxatin, Avastin in Cancer of the Ovary

Completed
2
132
US
Bevacizumab (Avastin®), Docetaxel (Taxotere®), Oxaliplatin (Eloxatin®)
Sanofi
Ovarian Cancer
08/11
08/11
NCT01588964: IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Completed
2
30
Europe
HIPEC, IPHC, Hypertermic intraperitoneal chemotherapy
Catholic University of the Sacred Heart
Ovarian Epithelial Cancer Recurrent
10/11
12/11
NCT01338792: Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Completed
2
47
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, pemetrexed disodium, ALIMTA, LY231514, MTA, questionnaire administration, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, RT-PCR, polymorphism analysis
University of Southern California, National Cancer Institute (NCI)
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
12/11
12/12
NCT00476086: Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus

Completed
2
20
US
Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Radiation
Dana-Farber Cancer Institute, Sanofi, Brigham and Women's Hospital, Massachusetts General Hospital
Mixed Mullerian Tumors of the Uterus
03/12
12/15
NCT01017809: Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer

Withdrawn
2
0
US
Aprepitant, Emend
NYU Langone Health
Ovarian Cancer
12/12
12/13
NCT01487720: GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

Completed
2
33
RoW
GEMOX
Asan Medical Center
Prostate Cancer
10/13
10/13
NCT00959647: A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Completed
2
19
US
Vismodegib, Erivedge, GDC-0449, RO5450815, FOLFOX, FOLFIRI, Bevacizumab, Avastin
Genentech, Inc.
Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
01/14
01/14
NCT01481701: A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma

Completed
2
90
Europe
Oxaliplatin, No other intervention, oxaliplatin
Jules Bordet Institute
Ovarian Carcinoma, Relapse
05/14
05/14
NCT00957905: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Completed
2
36
US
Alvocidib Hydrochloride, 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5, 7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, hydrochloride, (-)-cis-, Flavopiridol Hydrochloride, HL-275, HMR 1275, L-86-8275, L-868275, MDL 107,826A, MDL-107826A, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Actino-Hermal, Adrucil, Arumel, Cytosafe, Efudex, Efurix, Fiverocil, Fluoro Uracil, Fluoroplex, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Flurox, Ribofluor, Ro 2-9757, Ro-2-9757, Timazin, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669
National Cancer Institute (NCI)
Recurrent Extragonadal Seminoma, Recurrent Malignant Extragonadal Germ Cell Tumor, Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage III Testicular Cancer, Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Ovarian Germ Cell Tumor
08/14
08/14
NCT01936974: (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

Terminated
2
7
US
Gemcitabine, Gemzar, Bevacizumab, Avastin, Carboplatin, Paraplatin, Cisplatin, Platinol, Oxaliplatin, Eloxatin
Western Regional Medical Center
Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
08/15
08/15
NCT00183820: Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma

Completed
2
30
US
paclitaxel, gemcitabine, and oxaliplatin
University of Southern California, Sanofi
Testicular Cancer, Germ Cell Neoplasm
12/15
08/16
CORGI, NCT01016639: Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer

Completed
1/2
106
Europe
oxaliplatin, capecitabine, radiotherapy
Lund University Hospital, Roche Pharma AG, Sanofi-Synthelabo
Stomach Cancer, Gall Bladder Cancer, Bile Ductus Cancer, Pancreas Cancer, Colorectal Cancer
07/07
07/09

Download Options